Perspective from Michael E. Wechsler, MD, MMSc Dupilumab was more effective than omalizumab, benralizumab and mepolizumab in treating patients with severe asthma, according to a pair of abstracts ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

Exacerbations fell with omalizumab and mepolizumab for patients with asthma and obesity. Obesity did not decrease dupilumab’s rate of response in treating asthma. Tezepelumab may address type 2 ...

Omalizumab mechanism of action. Omalizumab binds to the Ce3 domain of immunoglobulin E (lgE) and prevents free lgE from binding to the mast cell FceRI receptor. Data courtesy of Genentech ...